High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: Results of the European group for bone marrow transplantation

John W. Sweetenham, Grace Liberti, Rachel Pearce, Golnaz Taghipour, Gino Santini, Anthony H. Goldstone

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Purpose: To investigate the results of treatment and factors that affect prognosis in adult patients undergoing high-dose therapy and autologous bone marrow transplantation (ABMT) for lymphoblastic lymphoma (LBL). Patients and Methods: The study was a retrospective analysis of 214 patients reported to the Lymphoma Registry of the European Group for Bone Marrow Transplantation (EBMT) between January 1981 and December 1992, including 105 patients undergoing marrow transplantation in first complete remission (CR). Data on all patients were reviewed, and analysis of prognostic factors conducted. Results: The actuarial overall survival rate at 6 years for the entire group is 42%. Disease status at ABMT was the major determinant of outcome: 6-year actuarial overall survival was 63% for patients transplanted in first CR, compared with 15% for those with resistant disease at the time of transplantation. Transplantation in second CR resulted in a 31% rate of actuarial overall survival at 6 years. For patients transplanted in first CR, univariate analysis failed to identify any factors at presentation that predicted for outcome after transplantation. Conclusion: These results suggest that ABMT is effective therapy for adults with LBL, even in patients with disease that is resistant to conventional-dose therapy. Results for patients transplanted in second CR are superior to those reported for conventional-dose salvage regimens. The results in first CR require verification in a prospective randomized clinical study.

Original languageEnglish (US)
Pages (from-to)1358-1365
Number of pages8
JournalJournal of Clinical Oncology
Volume12
Issue number7
DOIs
StatePublished - Jul 1994
Externally publishedYes

Fingerprint

Autologous Transplantation
Bone Marrow Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Transplantation
Therapeutics
Survival
Registries
Lymphoma
Survival Rate
Bone Marrow

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma : Results of the European group for bone marrow transplantation. / Sweetenham, John W.; Liberti, Grace; Pearce, Rachel; Taghipour, Golnaz; Santini, Gino; Goldstone, Anthony H.

In: Journal of Clinical Oncology, Vol. 12, No. 7, 07.1994, p. 1358-1365.

Research output: Contribution to journalArticle

@article{0e40a3e8749045e7b1bfdc3627cf2410,
title = "High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: Results of the European group for bone marrow transplantation",
abstract = "Purpose: To investigate the results of treatment and factors that affect prognosis in adult patients undergoing high-dose therapy and autologous bone marrow transplantation (ABMT) for lymphoblastic lymphoma (LBL). Patients and Methods: The study was a retrospective analysis of 214 patients reported to the Lymphoma Registry of the European Group for Bone Marrow Transplantation (EBMT) between January 1981 and December 1992, including 105 patients undergoing marrow transplantation in first complete remission (CR). Data on all patients were reviewed, and analysis of prognostic factors conducted. Results: The actuarial overall survival rate at 6 years for the entire group is 42{\%}. Disease status at ABMT was the major determinant of outcome: 6-year actuarial overall survival was 63{\%} for patients transplanted in first CR, compared with 15{\%} for those with resistant disease at the time of transplantation. Transplantation in second CR resulted in a 31{\%} rate of actuarial overall survival at 6 years. For patients transplanted in first CR, univariate analysis failed to identify any factors at presentation that predicted for outcome after transplantation. Conclusion: These results suggest that ABMT is effective therapy for adults with LBL, even in patients with disease that is resistant to conventional-dose therapy. Results for patients transplanted in second CR are superior to those reported for conventional-dose salvage regimens. The results in first CR require verification in a prospective randomized clinical study.",
author = "Sweetenham, {John W.} and Grace Liberti and Rachel Pearce and Golnaz Taghipour and Gino Santini and Goldstone, {Anthony H.}",
year = "1994",
month = "7",
doi = "10.1200/JCO.1994.12.7.1358",
language = "English (US)",
volume = "12",
pages = "1358--1365",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma

T2 - Results of the European group for bone marrow transplantation

AU - Sweetenham, John W.

AU - Liberti, Grace

AU - Pearce, Rachel

AU - Taghipour, Golnaz

AU - Santini, Gino

AU - Goldstone, Anthony H.

PY - 1994/7

Y1 - 1994/7

N2 - Purpose: To investigate the results of treatment and factors that affect prognosis in adult patients undergoing high-dose therapy and autologous bone marrow transplantation (ABMT) for lymphoblastic lymphoma (LBL). Patients and Methods: The study was a retrospective analysis of 214 patients reported to the Lymphoma Registry of the European Group for Bone Marrow Transplantation (EBMT) between January 1981 and December 1992, including 105 patients undergoing marrow transplantation in first complete remission (CR). Data on all patients were reviewed, and analysis of prognostic factors conducted. Results: The actuarial overall survival rate at 6 years for the entire group is 42%. Disease status at ABMT was the major determinant of outcome: 6-year actuarial overall survival was 63% for patients transplanted in first CR, compared with 15% for those with resistant disease at the time of transplantation. Transplantation in second CR resulted in a 31% rate of actuarial overall survival at 6 years. For patients transplanted in first CR, univariate analysis failed to identify any factors at presentation that predicted for outcome after transplantation. Conclusion: These results suggest that ABMT is effective therapy for adults with LBL, even in patients with disease that is resistant to conventional-dose therapy. Results for patients transplanted in second CR are superior to those reported for conventional-dose salvage regimens. The results in first CR require verification in a prospective randomized clinical study.

AB - Purpose: To investigate the results of treatment and factors that affect prognosis in adult patients undergoing high-dose therapy and autologous bone marrow transplantation (ABMT) for lymphoblastic lymphoma (LBL). Patients and Methods: The study was a retrospective analysis of 214 patients reported to the Lymphoma Registry of the European Group for Bone Marrow Transplantation (EBMT) between January 1981 and December 1992, including 105 patients undergoing marrow transplantation in first complete remission (CR). Data on all patients were reviewed, and analysis of prognostic factors conducted. Results: The actuarial overall survival rate at 6 years for the entire group is 42%. Disease status at ABMT was the major determinant of outcome: 6-year actuarial overall survival was 63% for patients transplanted in first CR, compared with 15% for those with resistant disease at the time of transplantation. Transplantation in second CR resulted in a 31% rate of actuarial overall survival at 6 years. For patients transplanted in first CR, univariate analysis failed to identify any factors at presentation that predicted for outcome after transplantation. Conclusion: These results suggest that ABMT is effective therapy for adults with LBL, even in patients with disease that is resistant to conventional-dose therapy. Results for patients transplanted in second CR are superior to those reported for conventional-dose salvage regimens. The results in first CR require verification in a prospective randomized clinical study.

UR - http://www.scopus.com/inward/record.url?scp=0028341009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028341009&partnerID=8YFLogxK

U2 - 10.1200/JCO.1994.12.7.1358

DO - 10.1200/JCO.1994.12.7.1358

M3 - Article

C2 - 8021726

AN - SCOPUS:0028341009

VL - 12

SP - 1358

EP - 1365

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -